Hologic receives CE Mark for CMV detection assay

By LabPulse.com staff writers

June 23, 2021 -- Hologic has received the CE Mark for its molecular assay to quantify human cytomegalovirus (CMV). The assay is the company's first test for transplant pathogen monitoring.

The Aptima CMV Quant assay quantifies the viral load of CMV and is intended for use in aiding in diagnosis and management of solid-organ transplant patients and hematopoietic stem cell transplant patients.

The in vitro nucleic acid amplification test uses real-time transcription-mediated amplification technology on the fully automated Panther system. The test can only be used with human plasma and whole blood samples.

Ink dries on Hologic's deal to buy Mobidiag
Hologic announced the completion of its $808 million acquisition of biotechnology company Mobidiag. The Finnish-French company develops near-patient,...
Hologic's growth continues in Q2
Hologic has continued to post significant increases in revenue, with revenues doubling in the company's second quarter. The growth was driven primarily...
Hologic acquires Mobidiag for $795M
Hologic announced it has agreed to acquire Mobidiag, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests...
Hologic wraps up Biotheranostics acquisition
Hologic has completed the acquisition of cancer test developer Biotheranostics. Hologic is gaining access to two laboratory-developed tests as part of...
Hologic inks deal with Google to unite cloud with diagnostics
Hologic has announced a collaboration with Google designed to advance the potential of digital diagnostics for cervical cancer screening by making Google...

Copyright © 2021 LabPulse.com

Last Updated ls 6/23/2021 1:25:47 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current